Dry powder inhalations containing thymopentin and its immunomodulating effects in Wistar rats

European Journal of Pharmaceutical Sciences

Volumn 36, Issue 4-5, 2009, Pages 572-579

  Gao, Jing ^a   Ding, Xueying ^a   Chu, Cang ^a   Lu, Lei ^a   Zhang, Yi ^a   Chen, Yan ^a   Fan, Wei ^a   Li, Guodong ^a   Gao, Shen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Dry powder; Immunomodulating; Inhalation; Thymopentin

Indexed keywords

CYCLOPHOSPHAMIDE; LACTOSE; LEUCINE; MANNITOL; THYMOPENTIN;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENSITY; DRY POWDER; FEMALE; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; SPLEEN; SPRAY DRYING; T LYMPHOCYTE SUBPOPULATION; THYMUS; WISTAR RAT; X RAY DIFFRACTION;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; BODY WEIGHT; FLOW CYTOMETRY; IMMUNOLOGIC FACTORS; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POWDERS; RATS; RATS, WISTAR; T-LYMPHOCYTE SUBSETS; THYMOPENTIN;

EID: 59349106652     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.12.004     Document Type: Article

References (28)

1. Arechavala A., Baiges D., Negroni R., and Alonso B. Study of some lymphocyte subset counts and cytokine levels in cryptococcosis associated with AIDS. Rev. Iberoam Micol. 14 (1997) 160-163
2. Bernengo M.G., Doveil G.C., Meregalli M., Appino A., and Massobrio R. Immunomodulation and Sezary syndrome: experience with thymopentin (TP-5). Br. J. Dermatol. 119 (1988) 207-221
3. Bosquillon C., Preat V., and Vanbever R. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J. Control. Rel. 96 (2004) 233-244
4. Cipolla D.C., Clark A.R., Chan H.K., Gonda I., and Shire S.J. Assessment of aerosol delivery system for recombinant human deoxyribonuclease. STP Pharma Sci. 4 (1994) 50-60
5. Colle R., Ceschia T., Colatritto A., and Biffoni F. Use of thymopentin in autoimmune hemolytic anemia due to chronic lymphocytic leukemia. Curr. Ther. Res. 44 (1988) 1045-1049
6. Corrigan O.I. Thermal analysis of spray dried products. Thermochim. Acta 248 (1995) 245-258
7. Costantino H.R., Andya J.D., Nguyen P.A., Dasovich N., Sweeney T.D., Shire S.J., Hsu C.C., and Maa Y.F. Effect of mannitol crystallization on the stability and aerosol performance of a spray-dried pharmaceutical protein, recombinant humanized anti-IgE monoclonal antibody. J. Pharm. Sci. 87 (1998) 1406-1411
8. Cowley S.C., Hamilton E., Frelinger J.A., Su J., Forman J., and Elkins K.L. CD4-CD8-T cells control intracellular bacterial infections both in vitro and in vivo. J. Exp. Med. 202 (2005) 309-319
9. Faist M., Ertel W., Salmen B., Weiler A., Ressel C., Bolla K., and Heberer G. The immune-enhancing effect of perioperative thymopentin administration in elderly patients undergoing major surgery. Arch. Surg. 123 (1988) 1449-1453
10. Gliniski J., Chavepeyer G., and Platten J.K. Surface properties of aqueous solutions of l-leucine. Biophys. Chem. 84 (2000) 99-103
11. Goldstein G., Scheid M.P., Boyse E.A., Schlesinger D.H., and Wauwe V.J. A synthetic entapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science 204 (1979) 1309-1310
12. Gonser S., Weber E., and Folkers G. Peptides and polypeptides as modulators of the immune response: thymopentin-an example with unknown mode of action. Pharmaceut. Acta Helv. 73 (1999) 265-273
13. He W., Zhang Z., Jiang X., Nie Y., and Wu F. Stability evaluation of thymopentin in preparation process. Sichuan Da Xue Xue Bao Yi Xue Ban 34 (2003) 292-294 Chinese
14. Hussian A., Arnold J.J., Khan M.A., and Ahsan F. Absorption enhancers in pulmonary protein delivery. J. Control. Rel. 94 (2004) 15-24
15. Irngartinger M., Camuglia V., Damm M., Goede J., and Frijlink H.W. Pulmonary delivery of therapeutic peptides via dry powder inhalation: effects of micronisation and manufacturing. Eur. J. Pharm. Biopharm. 58 (2004) 7-14
16. Jiang R.G., Wang C.L., Wang L.Q., Pan W.S., and Liu H. Effects of l-leucine on properties of interferon dry powder inhalations. Chin. J. Pharm. 36 (2005) 747-750 Chinese
17. Larhrib H., Martin G.P., Marriott C., and Prime D. The influence of carrier and drug morphology on drug delivery from dry powder formulations. Int. J. Pharm. 257 (2003) 283-296
18. Li H.Y., Seville P.C., Williamson I.J., and Birchall J.C. The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy. J. Gene Med. 7 (2005) 343-353
19. McMahon G.T., and Arky R.A. Inhaled insulin for diabetes mellitus. N. Engl. J. Med. 356 (2007) 497-502
20. Merigan T.C., Hirsch R.L., Fisher A.C., Meyerson L.A., Goldstein G., and Winters M.A. The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+T cells on progression of HIV disease in a double-blind study of thymopentin. AIDS 10 (1996) 159-165
21. Okamoto H., Todo H., Iida K., and Danjo K. Dry powders for pulmonary delivery of peptides and proteins. KONA 20 (2002) 71-83
22. Rajnavolgyi E., Kulics J., Szilagyvari M., Kisfaludy L., Nyeki O., and Schon I. The influence of new thymopoietin derivatives on the immune response of inbred mice. Int. J. Immunopharmacol. 8 (1986) 167-177
23. Seville P.C., Learoyd T.P., Li H.Y., Williamson I.J., and Birchall J.C. Amino acid-modified spray-dried powders with enhanced aerosolisation properties for pulmonary drug delivery. Powder Technol. 178 (2007) 40-50
24. Sun D.L., Shen P.Z., Wang Y.F., Chen H.P., Wu H.G., and Zhai D.D. Effect of medicinal vesiculation on hematopoeisis function of rats treated by cyclophosphamide chemotherapy. Zhejiang Zhongyi Xueyuan Xuebao 24 (2000) 74-78 Chinese
25. Tang S., Yuan X., Zhang Z.R., Song Q.G., and He Q. Research on thymopentin-loaded N-trimethyl chitosan nanoparticles administered through mouth. Sichuan Da Xue Xue Bao Yi Xue Ban 38 (2007) 885-888 Chinese
26. Tischio J.P., Patrick J.E., Weintraub H.S., Chasin M., and Goldstein G. Short in vitro half-life of thymopoietin 32-36 pentapeptide in human plasma. Int. J. Pept. Protein Res. 14 (1979) 479-484
27. Weaver A.L., Churchill M.A., and Jacobs A.J. Treatment of refractory rheumatoid arthritis with thymopoitin pentapeptide. Arthritis Rheum. 27 Suppl. (1984) B86
28. Xiong L.J., and Zhu J.B. Preparation and pharmaceutical properties of salcatonin dry powder inhalations. Acta Pharmaceut. Sin. 38 (2003) 218-222